YASUTOSHI FUJII

Last Updated :2024/10/02

Affiliations, Positions
Hiroshima University Hospital(Medical), Assistant Professor
E-mail
fujiiyasuhiroshima-u.ac.jp

Basic Information

Academic Degrees

  • Hiroshima University

Research Activities

Academic Papers

  1. Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study, Jpn J Clin Oncol, 20240207
  2. Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma, Cancer Med, 202405
  3. Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs, Hepatol Res, 20240527
  4. Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial, Yonago Acta Med, 20231107
  5. Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions, Cancers, 20230130
  6. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure, Hepatol Int, 202310
  7. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein, Cancers, 20230414
  8. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes, Eur J Gastroenterol Hepatol, 20230901
  9. Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failure, J Gastroenterol Hepatol, 202309
  10. Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment, Cancers, 20230824
  11. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma, Commun Med, 20231025
  12. Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma, Cancers, 20231114
  13. Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 36(4), 430-437, 202404
    Link to Paper Search Results by DOI
  14. ★, Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma, CANCERS, 16(7), 202404
    Link to Paper Search Results by DOI

Invited Lecture, Oral Presentation, Poster Presentation

  1. Peripheral T cell subpopulations during atezolizumab plus bevacizumab treatment for hepatocellular carcinoma, 2024/02/22, Without Invitation, English